TAP Holdings Inc. Licenses Compounds to Treat Helicobacter Pylori Infection

Strategic Insights -

TAP Holdings Inc. has entered into a licensing agreement with RPMS Technology Ltd. to develop and commercialize compounds that have shown potent in vitro activity against Helicobacter pylori (H. pylori) bacteria. H. pylori infection has been linked to gastric-related conditions, including ulcers and gastric carcinoma. The agreement grants TAP exclusive worldwide rights to these compounds, which have demonstrated great potential in treating H. pylori infection. This licensing agreement aligns with TAP's commitment to finding innovative compounds for the treatment and management of gastric-related conditions.

Key Takeaways:

  • TAP Holdings Inc. has licensed compounds from RPMS Technology Ltd. that have shown significant activity against H. pylori bacteria.
  • The compounds have demonstrated great potential in treating H. pylori infection, which is linked to gastric-related conditions such as ulcers and gastric carcinoma.
  • TAP has exclusive worldwide rights to develop and commercialize the compounds, which is a key component of its long-term strategy in the marketplace.
  • TAP recently received marketing clearance from the U.S. Food and Drug Administration (FDA) to market Prevacid (lansoprazole) Delayed-Release Capsules for various gastrointestinal conditions.
  • The company also markets Lupron (leuprolide acetate) Injection and Lupron Depot (leuprolide acetate for depot suspension) for various endocrine and oncology indications.
  • TAP Holdings Inc. is a joint venture between Abbott Laboratories and Takeda Chemical Industries, Ltd.
  • Graham Taylor, Ph.D., of the Royal Postgraduate Medical School, has stated that the compounds have shown great potential in treating H. pylori infection.

Statistics:

  • TAP Holdings Inc. was established in 1977 as TAP Pharmaceuticals Inc.
  • The company has twice received marketing clearance from the FDA in the past decade for Prevacid and Lupron/Lupron Depot.
  • H. pylori infection is linked to a significant proportion of gastric-related conditions, including ulcers and gastric carcinoma.
  • The Royal Postgraduate Medical School in London is the parent organization of RPMS Technology, which has completed extensive laboratory tests on the compounds.

Sources:

  • PRNewswire, "TAP Holdings Inc. Licenses Compounds for Treatment of Gastric-Related Conditions from RPMS Technology Ltd.," September 6, 1995.
  • Abbott Laboratories (NYSE: ABT) Company Profile.
  • Takeda Chemical Industries, Ltd. Company Profile.
  • FDA Website, Approval Dates for TAP Pharmaceuticals Inc. Products.